Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen.
PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers
of the tumor tissue, compared with LY353381, in treating women with newly diagnosed breast
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center